NCT04804254 - Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions

B-cell Lymphoma

Interventions

DRUG

ABBV-623

Oral Tablets

DRUG

ABBV-992

Oral Tablets

Trial Locations (5)

Dokuz Eylul University Medical Faculty /ID# 226085, Izmir

The Chaim Sheba Medical Center /ID# 226754, Ramat Gan

Tel Aviv Sourasky Medical Center /ID# 226755, Tel Aviv

Hospital del Centro Comprensivo de Cancer de la UPR /ID# 225646, San Juan

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 226087, Ankara